Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK

Current Medical Research and Opinion

Volumn 24, Issue 11, 2008, Pages 3275-3285

  Davies, Andrew ^a   Vardeva, Kawitha ^b   Loze, Jean Yves ^c   L'Italien, Gilbert J ^b,d   Sennfalt, Karin ^b   Van Baardewijk, Marc ^b  

^a ICON PLC   (United Kingdom)

^b BRISTOL MYERS SQUIBB   (United States)

^c Otsuka Pharmaceuticals France   (France)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotic agents; Aripiprazole; Cost effectiveness; Cost utility; Pharmacoeconomics; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; BENZATROPINE MESILATE; BROMOCRIPTINE; CLOZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; TETRAHYDROLIPSTATIN;

ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG COST; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYNDROME; HEALTH CARE UTILIZATION; HIGH RISK POPULATION; HUMAN; HYPERPROLACTINEMIA; MORTALITY; MULTICENTER STUDY; PROBABILITY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT WITHDRAWAL; UNITED KINGDOM; WEIGHT GAIN;

ALGORITHMS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLINICAL TRIALS, PHASE I AS TOPIC; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; FOLLOW-UP STUDIES; GREAT BRITAIN; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; PATIENT ACCEPTANCE OF HEALTH CARE; PIPERAZINES; QUALITY-ADJUSTED LIFE YEARS; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA;

EID: 67349174087     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990802507547     Document Type: Article

References (36)

1. National Institute for Health and Clinical Excellence. Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. London: National Institute for Clinical Excellence, 2002
2. Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 1997;171:502-508 (Pubitemid 27527317)
3. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000;177:212-217 (Pubitemid 30707552)
4. Taylor D, Paton K, Kerwin R. The South London & Maudsley NHS Trust & OXLEAS NHS Foundation Trust. 9th ed. London: Informa Healthcare, 2007
5. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209- 1223 (Pubitemid 41345943)
6. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006;163(4):600-610 (Pubitemid 44464569)
7. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006;163(4):611-622 (Pubitemid 44464570)
8. Chrzanowski WK, Marcus RN, Torbeyns A, et al. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl) 2006;189(2):259-266 (Pubitemid 44691547)
9. Pigott TA, Carson WH, Saha AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003;64(9):1048-1056 (Pubitemid 37158250)
10. Moeller KE, Shireman TI, Liskow BI. Relapse rates in patients with schizophrenia receiving aripiprazole in comparison with other atypical antipsychotics. J Clin Psychiatry 2006;67(12):1942-1947 (Pubitemid 46048192)
11. Haro JM, Salvador-Carulla L. The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia. CNS Drugs 2006;20(4):293-301
12. Reaney MD, Lees M, Wild D, et al. Using direct utility elicitation to assess the impact of schizophrenia and schizophrenia treatment-related adverse effects on quality of life: A patient study. J Psychopharmacology, 2006:20(5)Suppl TA17
13. Ulcickas Yood M, deLorenze G, Quesenberry CPJ, et al. The incidence of diabetes in atypical antipsychotic users differs according to agent: results from a multisite epidemiologic study. International Society of Pharmacoepidemiology 2007; Toronto, Canada; 2007.
14. Novartis Pharmaceuticals UK Ltd. Clozapine (Clozaril) Summary of Product Characteristics. Frimley, Surrey, 2005.
15. Leibson CL, Burke JP, Ransom JE, et al. Relative risk of mortality associated with diabetes as a function of birth weight. Diabetes Care 2005;28(12):2839-2843 (Pubitemid 43942912)
16. Farahati F, Boucher M, Moulton K, et al. Atypical antipsychotic monotherapy for schizophrenia: clinical review and economic evaluation of first year of treatment [Technology report number 91]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2007
17. Thompson A, Shaw M, Harrison G, et al. Patterns of hospital admission for adult psychiatric illness in England: analysis of Hospital Episode Statistics data. Br J Psychiatry 2004;185:334-341 (Pubitemid 39331336)
18. Curtis L, Netten A. Unit costs of health and social care. Canterbury: Personal Social Services Research Unit, University of Kent; 2006.
19. UK Prospective Diabetes Study Group. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. BMJ 1998;317(7160):720-726 (Pubitemid 28414302)
20. Hansen KA. Hyperprolactinemia and the Dopamine Receptor. US Endocrine Disease, 2006. Available at: http://www.touch briefings.com/pdf/1815/hansenpdf (last accessed April 2008)
21. Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev 2007;(1):005148 (Pubitemid 351820500)
22. British National Formulary 53. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2007.
23. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000;17(5):479-500 (Pubitemid 30398806)
24. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001;10(8):779-787 (Pubitemid 34041389)
25. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London; 2004.
26. Kane JM, Osuntoken O, Kryzhanovskaya LA, et al. A 28-week randomised, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia Presented at: 161st Annual Meeting of the American Psychiatric Association, Washington, DC, 2008.
27. Kasper S, Winkler D. Addressing the limitations of the CATIE study. World J Biol Psychiatry 2006;7:126-127 (Pubitemid 43738912)
28. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006;63(10):1079-1087 (Pubitemid 44498387)
29. Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry 2004;161(9):1709-1711 (Pubitemid 39201473)
30. Miller EA, Leslie DL, Rosenheck RA. Incidence of newonset diabetes mellitus among patients receiving atypical neuroleptics in the treatment of mental illness: evidence from a privately insured population. J Nerv Ment Dis 2005;193(6):387-395 (Pubitemid 40800628)
31. Rosenheck RA, Leslie DL, Sindelar J, et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 2006;163(12):2080-2089 (Pubitemid 46114227)
32. Bagnall A, Jones L, Ginnelly L, et al. A rapid and systematic review of atypical antipsychotics in schizophrenia. York: NHS Centre for Reviews and Dissemination, 2001
33. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19(1):1-93 (Pubitemid 40677047)
34. ADA/APA/AACE/NAASO. Consensus development conference on antipsychotic drugs and obesity and diabetes. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Diabetes Care 2004;27(2):596-601.
35. De Hert M, Hanssens L, van Winkel R, et al. Reversibility of Antipsychotic Treatment-Related Diabetes in Patients With Schizophrenia. Diabetes Care 2006;29:2329-2330
36. De Hert M, Hanssens L, van Winkel R, et al. A Case Series: Evaluation of the Metabolic Safety of Aripiprazole. Schizophrenia Bull 2007;33(33):823-830 (Pubitemid 47343707)